An experimental lung cancer drug developed by Akeso and licensed globally by Summit Therapeutics delivered one of the most closely watched oncology results of the year. The drug reduced the risk of death by 34% during a late-stage clinical trial conducted in China. As a result, the findings immediately intensified discussions across the pharmaceutical industry about whether a new generation of cancer therapies could eventually challenge dominant treatments such as Keytruda.
The drug, called ivonescimab, combines two therapeutic mechanisms into a single bispecific antibody. It simultaneously targets PD-1, an immune checkpoint protein involved in suppressing immune responses against tumors. Additionally, it targets VEGF, a protein associated with blood vessel formation that helps cancers grow and spread.
Researchers presented the data ahead of the annual oncology conference organized by asco. At this event, multiple pharmaceutical companies are unveiling next-generation lung cancer therapies expected to reshape treatment standards during the next decade.
When combined with chemotherapy, the experimental lung cancer drug extended median overall survival for patients with squamous non-small-cell lung cancer to 27.9 months. Patients receiving the standard combination of immunotherapy and chemotherapy survived a median of 23.7 months. Furthermore, the four-month improvement achieved statistical significance in the Phase 3 study.
The trial focused specifically on squamous lung cancer, one of the most difficult forms of the disease to treat effectively. Physicians have historically faced limited progress in extending survival for these patients, particularly because many therapies produce only incremental gains.
Experimental Lung Cancer Drug Shows Survival Benefit in Difficult Patient Population
The latest results strengthened confidence in ivonescimab after earlier studies demonstrated that the treatment successfully delayed tumor progression. However, many oncologists remained cautious because previous VEGF-targeting therapies often improved progression-free survival without extending overall survival rates.
The new data now suggests the experimental lung cancer drug may achieve both objectives simultaneously.
Ivonescimab has become one of the most debated therapies in modern oncology because it attempts to combine the benefits of checkpoint inhibitors and anti-angiogenic treatments into a single molecule. Keytruda, developed by Merck, transformed cancer treatment by helping the immune system recognize tumors more effectively. Moreover, Avastin, developed by Roche, targets blood vessel growth that nourishes cancer cells.
Industry analysts increasingly view bispecific antibody treatments as a major commercial opportunity. Market interest accelerated after Summit Therapeutics licensed rights to ivonescimab outside China. Since then, investor enthusiasm surrounding the drug has dramatically increased. Company information and oncology pipeline updates remain available through summitplc.
Still, several oncologists urged caution when interpreting the findings. Because the Phase 3 study enrolled patients exclusively in China, researchers continue debating whether identical results will occur in broader global populations.
Some previous studies have suggested that Chinese patients respond more favorably to standalone PD-1 and VEGF therapies compared with Western populations. Due to that uncertainty, Summit Therapeutics continues running the international Harmoni-3 trial involving patients across multiple countries.
Researchers also highlighted the importance of evaluating quality of life alongside survival benefits. While extending survival by four months may represent a meaningful advance for many patients, specialists noted that the practical significance often depends on treatment tolerability, side effects, and individual patient circumstances.
Ivonescimab Fuels Global Race to Replace Keytruda in Oncology
The broader oncology industry is closely watching ivonescimab because pharmaceutical companies are racing to identify therapies capable of succeeding blockbuster checkpoint inhibitors such as Keytruda and Opdivo. Those drugs fundamentally changed cancer care. Additionally, they generated tens of billions of USD in annual revenue.
Keytruda alone produced more than USD 30 billion in sales last year and currently holds dozens of approved indications across multiple cancer types. Additionally, product information related to Keytruda and immunotherapy research can be reviewed at merck.
The possibility of replacing or complementing existing checkpoint inhibitors has triggered aggressive competition among biotechnology firms and multinational pharmaceutical companies. Licensing agreements involving PD-1-related therapies reached approximately USD 30 billion during the past year, nearly doubling previous industry records.
Despite the excitement, experts remain uncertain whether PD-1/VEGF drugs will achieve the same widespread adoption as Keytruda. Competition in oncology has intensified considerably over the last decade, especially with the emergence of antibody-drug conjugates and highly personalized cancer therapies.
Another concern involves safety. In the latest study, bleeding events occurred in nearly one-quarter of patients treated with ivonescimab. Severe bleeding remained relatively uncommon, but rates were still higher than those observed in the control group receiving traditional immunotherapy.
That issue carries particular importance in squamous lung cancer because tumors frequently develop near major blood vessels. Blocking VEGF activity can sometimes interfere with blood vessel repair mechanisms, potentially increasing the risk of hemorrhaging.
Global regulators and oncology researchers will now closely monitor results from ongoing international studies. This is to determine whether the experimental lung cancer drug can maintain comparable survival benefits across broader patient populations. Additionally, clinical research information involving lung cancer therapies and regulatory development continues to be published through clinical trials.
